GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Therapeutics Inc (NAS:APLT) » Definitions » Price-to-Free-Cash-Flow

Applied Therapeutics (Applied Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Apr. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Applied Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-04-25), Applied Therapeutics's share price is $4.23. Applied Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.65. Hence, Applied Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Applied Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

APLT's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.19
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Applied Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.15. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.65.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 43.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 11.00% per year.

During the past 7 years, Applied Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 43.10% per year. The lowest was -116.90% per year. And the median was -16.35% per year.


Applied Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Applied Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Therapeutics Price-to-Free-Cash-Flow Chart

Applied Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Applied Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Applied Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Applied Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Applied Therapeutics's Price-to-Free-Cash-Flow falls into.



Applied Therapeutics Price-to-Free-Cash-Flow Calculation

Applied Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=4.23/-0.648
=N/A

Applied Therapeutics's Share Price of today is $4.23.
Applied Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.65.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Applied Therapeutics  (NAS:APLT) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Applied Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Applied Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied Therapeutics (Applied Therapeutics) Business Description

Traded in Other Exchanges
Address
545 Fifth Avenue, Suite 1400, New York, NY, USA, 10017
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need.
Executives
Stacy J. Kanter director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Shoshana Shendelman director, 10 percent owner, officer: President and CEO C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Adam Hansard officer: Chief Commercial Officer C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE, SUITE 1400, NEW YORK NY 10017
Riccardo Perfetti officer: Chief Medical Officer C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Alexandria Real Estate Equities, Inc. 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Catherine Thorpe officer: Chief Accounting Officer 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Chids Mahadevan officer: Chief Accounting Officer C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Steven A. Ortega officer: Principal Accounting Officer C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Charles Silberstein officer: Chief Financial Officer C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Leslie D. Funtleyder director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Joel S Marcus director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Alexandria Equities No. 7, Llc 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Jay S Skyler director DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005
Alexandria Venture Investments, Llc 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Teena Lerner director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173

Applied Therapeutics (Applied Therapeutics) Headlines

From GuruFocus